In June 2024 CEHURD in collaboration with the Kenya Legal and Ethical Issues Network on HIV/AIDs (KELIN) conducted a Market Intelligence Study with support from the International Treatment Preparedness Coalition (ITPC) Global.  This study report focused on identifying priority health products for intervention, specifically targeting HIV and TB, with inclusion of Hepatitis C (HCV) and cervical cancer.

This study report highlights the WHO Hepatitis global report of 2024 which estimated a total of hepatitis C infections (all ages) in Uganda at 356,043 with Hepatitis C incidence at 5,678 and number of deaths caused by hepatitis C infection at 723. Unfortunately, the study found that the diagnosis coverage (total) was as low as 9% by end of 2022 with treatment coverage, (of all infected) at 0% at the end 2022. According to the market intelligence study report, the prevalence of chronic HCV (RNA+/cAg) in Uganda is 0.75% as at (2022), and the prevalence of chronic HCV (RNA+/cAg) among persons who inject drugs is 20.6% (2017).